BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). After surgery, participants will receive local standard-of-care treatment and will be followed for safety, efficacy, and survival for up to 2 years.
This trial contains a safety run-in to evaluate the safety and tolerability of the two treatment arms: Arm A (TransCon TLR7/8 Agonist plus pembrolizumab) and Arm B (TransCon TLR7/8 Agonist plus TransCon IL-2 β/γ). The safety run-in will be followed by the randomized Phase 2, open-label part of the trial comparing the safety, efficacy and survival of treatment Arm A or Arm B compared to treatment Arm C (pembrolizumab monotherapy).

开始日期2023-09-29

申办/合作机构

Ascendis Pharma A/S

NCT05081609

/ Recruiting临床1/2期

IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2 β/γ as monotherapy or in combination therapy in adult participants with advanced or metastatic solid tumors. Given the unique PK profile enabled by the TransCon technology, TransCon IL-2 β/γ presents the opportunity to enhance the therapeutic index of current IL-2 therapy.

开始日期2022-01-11

申办/合作机构

Ascendis Pharma Oncology Division A/S

100 项与 TransCon IL-2 beta/gamma(Ascendis Pharma) 相关的临床结果

登录后查看更多信息

100 项与 TransCon IL-2 beta/gamma(Ascendis Pharma) 相关的转化医学

登录后查看更多信息

100 项与 TransCon IL-2 beta/gamma(Ascendis Pharma) 相关的专利（医药）

登录后查看更多信息

100 项与 TransCon IL-2 beta/gamma(Ascendis Pharma) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期头颈部鳞状细胞癌	临床2期	美国	Ascendis Pharma A/S	2023-09-29
晚期头颈部鳞状细胞癌	临床2期	格鲁吉亚	Ascendis Pharma A/S	2023-09-29
晚期头颈部鳞状细胞癌	临床2期	德国	Ascendis Pharma A/S	2023-09-29
晚期头颈部鳞状细胞癌	临床2期	匈牙利	Ascendis Pharma A/S	2023-09-29
晚期头颈部鳞状细胞癌	临床2期	意大利	Ascendis Pharma A/S	2023-09-29
晚期头颈部鳞状细胞癌	临床2期	波兰	Ascendis Pharma A/S	2023-09-29
晚期头颈部鳞状细胞癌	临床2期	西班牙	Ascendis Pharma A/S	2023-09-29
晚期头颈部鳞状细胞癌	临床2期	中国台湾	Ascendis Pharma A/S	2023-09-29
局部晚期头颈部鳞状细胞癌	临床2期	美国	Ascendis Pharma A/S	2023-09-29
局部晚期头颈部鳞状细胞癌	临床2期	格鲁吉亚	Ascendis Pharma A/S	2023-09-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05081609 (IL Believe, ESMO2024)	临床2期	铂耐药性卵巢癌 cytotoxic lymphocytes (CLs)	12	TransCon IL-2 β/γ + Pemetrexed	繭願襯鏇鬱觸積鑰遞窪(廠觸獵齋襯網築齋憲鏇) = 66.7% 糧醖餘築糧願餘廠顧鬱 (齋淵壓廠鏇構夢願構蓋 ) 更多	积极	2024-09-14
NCT05081609 (IL-Believe, Biospace) 人工标引	临床1/2期	小细胞肺癌 \| 黑色素瘤 \| 结直肠癌	-	TransCon IL-2 β⁄γ +TransCon TLR7/8 Agonist (melanoma)	選製鬱壓糧襯網遞獵鹹(繭鬱願製夢膚鏇襯鹹構) = 獵繭鏇顧獵窪構膚襯繭鬱蓋築鹽膚鏇觸鏇糧壓 (積顧鏇衊鹽積築糧顧壓 )	积极	2024-06-03
				TransCon IL-2 β/γ (colorectal cancer)	網製觸鏇淵夢製願遞鏇(憲膚夢壓網築壓鑰選鹽) = 壓鑰廠醖築積齋獵繭鏇鏇遞製鹽鏇築製遞積壓 (選鏇積鬱壓壓願鑰築鏇 )
NCT05081609 (IL Believe, ASCO2024) 人工标引	临床1/2期	实体瘤 absolute lymphocyte counts (ALC) \| cytotoxic lymphocytes (CLs) \| soluble CD25 ... 更多	46	TransCon IL-2 β/γ alone	憲遞繭積製糧繭壓簾願(醖糧艱製鑰選簾廠窪蓋) = 餘積壓築醖艱顧構鹽鬱壓鑰願遞顧糧製齋願憲 (淵膚網夢艱鹹獵願鏇鹽 ) 更多	积极	2024-05-24
				TransCon IL-2 β/γ + pembrolizumab	憲遞繭積製糧繭壓簾願(醖糧艱製鑰選簾廠窪蓋) = 齋壓蓋鹹鹹鏇網遞願壓壓鑰願遞顧糧製齋願憲 (淵膚網夢艱鹹獵願鏇鹽 )
NCT05081609 (IL-Believe, ESMO 12023 \| ESMO 22023) 人工标引	临床1/2期	晚期恶性实体瘤	39	TransCon IL-2 β/γ (20 to 160 mcg/kg)	鬱醖齋選鏇選夢齋築選(廠蓋夢餘顧淵齋鬱齋獵) = 膚獵顧製簾夢憲襯選遞構鹽鑰遞蓋艱憲構淵壓 (淵鏇鹹鬱淵觸網鹹齋範 ) 更多	积极	2023-10-23
				TransCon IL-2 β/γ (20 to 80 mcg/kg) + pembrolizumab	鬱醖齋選鏇選夢齋築選(廠蓋夢餘顧淵齋鬱齋獵) = 醖獵鑰遞鏇齋觸壓窪窪構鹽鑰遞蓋艱憲構淵壓 (淵鏇鹹鬱淵觸網鹹齋範 )
NCT05081609 (IL Believe, ASCO 12023 \| ASCO 22023) 人工标引	临床1/2期	晚期恶性实体瘤	27	TransCon IL-2 β/γ	範衊構繭窪鹹鏇鬱蓋鹹(窪簾願製襯願廠衊鏇淵) = 1 Dose Limiting Toxicity of G3 CRS was reported at DL4. 蓋獵鹹構鏇範網積願網 (艱構襯遞憲顧憲醖獵衊 ) 更多	积极	2023-05-31
				TransCon IL-2 β/γ+Pembrolizumab